Systematic analysis of ZDHHC9 as a potential prognostic and immunotherapy biomarker in breast cancer.

Front Immunol · 2025 · PMC12307147 · PMID 40740766

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

Our data suggested an overall trend of ZDHHC9 upregulation and poor outcome across BC, but subtype-specific differences remain to be explored.

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.